Biohaven (BHVN) is back in focus after reporting first quarter results alongside filing an omnibus shelf registration, pairing a reduced net loss with fresh flexibility to issue a wide range of securities.

Those first quarter results and the new shelf registration arrive after a sharp reset, with the share price down 25.57% over 90 days and total shareholder return down 55.84% over one year. This points to fading momentum despite recent balance sheet flexibility.

If this kind of high risk biotech story interests you, it can be useful to compare it with other healthcare names using a focused screener, such as 32 healthcare AI stocks

With Biohaven’s share price under pressure and an omnibus shelf in place, the key question is whether the recent reset leaves the stock undervalued or if the market is already pricing in future pipeline progress.

Preferred Price-to-Book of 10.6x: Is it justified?

On a P/B basis, Biohaven trades at 10.6x, which sits below its direct peer group average of 20.3x but well above the broader US biotech sector at 2.4x.

P/B compares the company’s market value to its accounting equity, so it is often used for early stage biopharma where earnings and sales are not yet meaningful. For a business like Biohaven, which reported a loss of $647.677m and less than $1m in revenue, investors are effectively paying for the pipeline, management and balance sheet rather than current profit.

The current 10.6x multiple suggests the market is still assigning a premium to Biohaven’s asset base, even after a 55.84% decline in total shareholder return over the past year and a share price of $9.08. At the same time, this level is far below the 20.3x peer average. This indicates investors are either applying a discount to Biohaven’s specific risks or are less convinced about its portfolio relative to higher rated peers.

Compared with the US biotech industry average P/B of 2.4x, Biohaven’s valuation looks expensive on this metric, with the stock trading at more than four times the sector level. That gap highlights how much of Biohaven’s current market value rests on expectations for its extensive clinical and preclinical pipeline to translate into future revenue and, eventually, profitability.

Result: Price-to-Book of 10.6x (OVERVALUED)

However, there are still clear risks, including the company’s lack of current revenue and the possibility that key clinical programs do not advance as expected.

Next Steps

Given the mix of pressure and potential around Biohaven, does the current setup match your own risk and reward balance, or feel out of line with it? If you want to weigh the concerns against the upside yourself, start by reviewing the 1 key reward and 4 important warning signs

Looking for more investment ideas?

If Biohaven feels interesting but not quite enough on its own, broaden your watchlist with a few targeted ideas that could help inform your next steps.

• Spot opportunities others might overlook by scanning a screener containing 21 high quality undiscovered gems that surfaces companies with strong fundamentals before they hit the mainstream.
• Prioritise resilience by using a 70 resilient stocks with low risk scores that filters for stocks with more robust risk profiles than the broader market.
• Focus on quality balance sheets with a solid balance sheet and fundamentals stocks screener (44 results) that highlights companies combining financial strength with fundamental support.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.